Skip to main content
NKTR
NASDAQ Life Sciences

Nektar Therapeutics 公告 Q4 销售额下降至 2180 万美元，受设施出售和较低的特许权使用费影响

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$71.59
Mkt Cap
$1.969B
52W Low
$6.48
52W High
$75.67
Market data snapshot near publication time

summarizeSummary

Nektar Therapeutics 报告称其 Q4 收入下降至 2180 万美元，主要是由于 2024 年 12 月出售其在亨茨维尔的制造设施，导致产品销售额减少，并且非现金特许权使用费收入减少。该公司还公布了 Q4 每股亏损 -$1.78 和净亏损 -$3610 万。尽管该公司最近完成了 4.6 亿美元的公开发行以加强其财务状况，并计划启动 rezpegaldesleukin 的 3 期试验，但当前的财务结果反映了一个充满挑战的季度。交易者将密切关注公司管道和管理设施出售后的财务状况的进一步更新。

在该公告发布时，NKTR的交易价格为$71.59，交易所为NASDAQ，所属行业为Life Sciences，市值约为$19.7亿。 52周交易区间为$6.48至$75.67。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed NKTR - Latest Insights

NKTR
Apr 24, 2026, 4:16 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Nektar Therapeutics Seeks Shareholder Approval for 3 Million Share Increase in Incentive Plan
Sentiment: Neutral
View Wiseek Article
NKTR
Apr 23, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
9
Nektar Therapeutics Finalizes Upsized $373.75M Public Offering at Near-Market Price to Fund Phase 3 Trials
Sentiment: Positive
View Wiseek Article
NKTR
Apr 23, 2026, 6:02 AM EDT
Filing Type: 424B5
Importance Score:
8
Nektar Therapeutics Prices Upsized $325M Public Offering to Fund Phase 3 Clinical Trials
Sentiment: Neutral
View Wiseek Article
NKTR
Apr 21, 2026, 9:31 PM EDT
Source: Reuters
Importance Score:
8
Nektar Upsizes Public Offering to $325 Million, Prices Shares at $92.00
Sentiment: Negative
View Wiseek Article
NKTR
Apr 20, 2026, 5:00 PM EDT
Filing Type: 424B5
Importance Score:
8
Nektar Therapeutics Announces $250M Equity Offering to Fund Phase 3 Development
Sentiment: Positive
View Wiseek Article
NKTR
Apr 20, 2026, 4:58 PM EDT
Filing Type: 8-K
Importance Score:
8
Nektar Therapeutics Reports Strong $741.7M Cash Position Amidst Equity Offering
Sentiment: Positive
View Wiseek Article
NKTR
Apr 20, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Nektar Therapeutics Reports Positive 52-Week Phase 2b Results for Rezpegaldesleukin in Alopecia Areata, Advancing to Phase 3
Sentiment: Positive
View Wiseek Article
NKTR
Apr 20, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Nektar's Alopecia Treatment Shows Strong Phase 2 Results, Paving Way for Registrational Trials
Sentiment: Positive
View Wiseek Article
NKTR
Mar 12, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
7
Nektar Therapeutics Reports Q4 Sales Decline to $21.8M, Hurt by Facility Sale and Lower Royalties
Sentiment: Negative
View Wiseek Article
NKTR
Mar 12, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Nektar Therapeutics Secures Over $500M in Capital, Funds Phase 3 Trials Despite Q4 Losses
Sentiment: Positive
View Wiseek Article